FDA warns of buying Accutane online

Share this article:
The FDA launched a Web site warning of the dangers of purchasing Roche’s acne drug Accutane (isotretinoin) or any of its generic equivalents over the Internet.

The agency said the Web page, www.fda.gov/buyonline/accutane, will be positioned as a search result on Google and other search engines so that it is highly visible when a consumer initiates an online search for the drug under any one of its four names.

Isotretinoin is sold by generic manufacturers: Genpharm, maker of Amnesteem,  distributed by Mylan/Bertek; Ranbaxy Pharmaceuticals, maker of Sotret; and Barr Labs, maker of Claravis.
Although Web sales of isotretinoin is illegal, some consumers have turned to the Internet to circumvent a federal program designed to control access to the drug.

Last March, the FDA and manufacturers of isotretinoin initiated a distribution program, dubbed iPLEDGE, placing safeguards on sales of the drug to women who are pregnant.

Isotretinoin has been linked to severe birth defects as well as mental health problems and liver damage.

The drug is approved to treat severe acne in patients that do not respond to other treatments.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...